Mission Bio updates platform to expand heme-onc research

By The Science Advisory Board staff writers

September 8, 2021 -- Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.

The updates allow researchers to apply single-cell analysis to a wider range of projects due to new ready-to-use panels, Tapestri single-cell DNA published panels, and a lowered input threshold. Researchers now can access single-cell insights from as few as 20,000 cells while conserving samples.

BioLegend's expanded TotalSeq D antibodies catalog has also been added to Tapestri. The addition enables researchers to start with a predesigned heme-onc panel (or customize one to fit the needs of a specific project) and connect genomic data to a broader array of phenotypes, according to the firm.

Mission Bio is hosting a virtual launch event of its platform on September 21, 2021, at 8 a.m. Pacific time.

NanoString uses tech to assess ties between tumor cells and immune cells
NanoString Technologies is directing attention to research published online August 26 in Cell involving its GeoMx Digital Spatial Profiler technology.
Vizgen begins shipping Merscope instruments for single-cell genomics
Vizgen has shipped its first commercial Merscope instruments to research institutions as part of a limited summer release program. Merscope enables high-plex,...
Deepcell hits 1 billion images in cell morphology atlas
Deepcell, a life science company developing artificial intelligence-powered cell classification, announced that its cell morphology atlas now includes...
Immunitas nabs $58M for cancer therapy based on single-cell platform
Immunitas Therapeutics has completed a $58 million financing round that the company will use to advance its lead program, a natural killer and T-cell...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter